近年来代表性工作包括：

(1)发现肝癌靶标SIRT6首个功能激动剂MDL-800和结肠癌恶性转移靶标APC-Asef相互作用首个抑制剂MAIT-203(Nat Chem Biol, 2018; Nat Chem Biol, 2017)；

(2) 发展临床样本来源的全新靶标识别方法AlloDriver(Nucleic Acids Res, 2019; Am J Hum Genet, 2017)；

(3) 发展变构药物设计方法发现多种全新变构活性小分子(Nucleic Acids Res, 2019, 2018, 2016, 2014, 2011; J Med Chem, 2019, 2018a, 2018b; Bioinformatics, 2016, 2015, 2013)。

他引超过4000次，H因子为44，获国内外专利9项(第一发明人5项)。受邀以通讯作者在国际顶尖综述杂志Chem Rev (IF=52.613)、Chem Soc Rev (IF=40.182)撰写变构药物机制综述，均作为封面文章重点推荐；受美国化学会旗舰期刊Acc Chem Res (IF=20.9)特邀回顾申请人10年来引领变构药物设计领域发展的贡献；受Springer-Nature出版社邀请作为主编撰写国际首本变构药物发现类书Protein Allostery in Drug Discovery；常年担任Science、Nat Chem、Mol Cell等60余种SCI期刊审稿人，澳大利亚Austrian Science Fund (FWF)等基金和西班牙University of Barcelona等学校Tenure考核的国际评审人。由于在“精准靶标识别和First-in-class药物先导发现”方面的贡献，获得美国化学会Excellent Research Advisor、中国药学会生物医药创新奖、2017年中国十大科技新锐人物、Roche Creative Chemistry Award和药明康德生命化学研究奖等荣誉。

近5年代表性文章 (*为通讯作者)

1.          Lu S, Shen Q, Zhang J*. Allosteric methods and their applications: facilitating the discovery of allosteric drugs and the investigation of allosteric mechanisms. Acc Chem Res. 2019, 52(2): 492-500.

2.          Huang Z, Zhao J, Deng W, Chen Y, Shang J, Song K, Zhang L, Wang C, Lu S, Yang X, He B, Min J, Hu H, Tan M, Xu J, Zhang Q, Zhong J, Sun X, Mao Z, Lin H, Xiao M, Chin YE, Jiang H, Xu Y*, Chen G*, Zhang J*. Identification of a cellular active SIRT6 allosteric activator. Nat Chem Biol. 2018, 14(12): 1118-1126.

3.          Jiang H, Deng R, Yang X, Shang J, Lu S, Zhao Y, Song K, Liu X, Zhang Q, Chen Y, Chinn YE, Wu G, Li J, Chen G, Yu J*, Zhang J*. Peptidomimetic inhibitors of APC-Asef interaction block colorectal cancer migration. Nat Chem Biol. 2017, 13(9):994-1001.

4.          Lu S*, Ni D, Wang C, He X, Lin H, Wang Z*, Zhang J*. Deactivation pathway of Ras GTPase underlies conformational substates as targets for drug design. ACS Catalysis. 2019, 9(8): 7188-7196.

5.          Huang M, Song K, Liu X, Lu S, Shen Q, Wang R, Gao J, Hong Y, Li Q, Ni D, Xu J, Chen G, Zhang J*. AlloFinder: a strategy for allosteric modulator discovery and allosterome analyses. Nucleic Acids Res. 2018, 46: 451-458.

6.          Shen Q, Cheng F, Song H, Lu W, Zhao J, An X, Liu M, Chen G, Zhao Z*, Zhang J*. Proteome-scale investigation of protein allosteric regulation perturbed by somatic mutations in 7,000 cancer genomes. Am J Hum Genet. 2017, 100(1): 5-20.

7.          Shen Q, Wang G, Li S, Liu X, Lu S, Chen Z, Song K, Yan J, Geng L, Huang Z, Huang W, Cheng G, Zhang J*. ASD v3.0: unraveling allosteric regulation with structural mechanisms and biological networks. Nucleic Acids Res. 2016, 44: D527-535.

8.          Yang X, Zhong J, Zhang Q, Qian J, Song K, Ruan C, Xu J, Ding K, Zhang J*. Rational Design and Structure Validation of a Novel peptide Inhibitor of the Adenomatous Polyposis Coli (APC)-Rho Guanine Nucleotide Exchange Factor 4 (Asef) Interaction. J Med Chem. 2018, 61(17): 8017-8028.

9.          Li S, Shen Q, Su M, Liu X, Lu S, Chen Z, Wang R, Zhang J*. Alloscore: a method for predicting allosteric ligand-protein interactions. Bioinformatics. 2016, 32(10): 1574-1576.

10.        Lu S, Jang H, Muratcioglu S, Gursoy A, Keskin O, Nussinov R*, Zhang J*. Ras conformational ensembles, allostery and signaling. Chem Rev. 2016, 116(11): 6607-6665.